Plant Name: Berberis repens
Taxonomic Information:
Plant ID: NPO17959
Plant Latin Name: Berberis repens
Taxonomy Genus: Berberis
Taxonomy Family: Berberidaceae
Plant External Links:
NCBI TaxonomyDB:
559508
Plant-of-the-World-Online:
31531-2
Used in Medicines:
Unknown.
Geographical Distribution:
United States
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| RECQL; TDP1; GLO1; ALOX12; HSD17B2; HSD17B10; NOX4; APEX1; POLB; | |
| ACHE; | |
| TOP2A; | |
| AXL; MET; FLT3; CDK1; PIM1; KDR; CDK8; IGF1R; AURKB; | |
| CA2; CA12; CA7; CA4; | |
| TYR; | |
| AHR; HIF1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.471E-09 | 8.009E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.506E-09 | 2.070E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.234E-08 | 2.442E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.138E-08 | 5.300E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.000E-07 | 2.903E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.130E-07 | 5.232E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 1.564E-06 | 7.738E-04 | ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD17B10, HSD17B2, NOX4, TYR |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.317E-06 | 1.051E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.416E-06 | 1.074E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.830E-06 | 1.185E-03 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.439E-06 | 1.410E-03 | APEX1, AXL, CDK1, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.207E-06 | 2.531E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.860E-06 | 2.674E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.860E-06 | 2.674E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 2.798E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0007346; regulation of mitotic cell cycle | 1.159E-05 | 3.458E-03 | APEX1, AURKB, CDK1, CDK8, CYP1A1, L3MBTL1, PIM1, TOP2A |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.496E-05 | 4.230E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 1.556E-05 | 4.343E-03 | FLT3, HIF1A, KDR, L3MBTL1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.695E-05 | 4.556E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.926E-05 | 4.992E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.015E-05 | 5.044E-03 | AURKB, AXL, CDK1, CDK8, FLT3, IGF1R, KDR, MET, PIM1, RECQL, TOP2A |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.178E-05 | 5.330E-03 | AHR, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.228E-05 | 8.937E-03 | CYP1A2, CYP2C19 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.417E-05 | 9.159E-03 | AXL, FLT3, HIF1A, POLB |
| CC | GO:0016020; membrane | GO:0016020; membrane | 4.742E-05 | 9.742E-03 | ACHE, ALOX12, AXL, CA12, CA2, CA4, CDK1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, FLT3, GLO1, HSD17B10, HSD17B2, IGF1R, KDR, L3MBTL1, MET, NOX4, NPSR1, PIM1, RECQL, TDP1, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.439E-08 | 1.022E-06 | CA12, CA2, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.340E-06 | 4.759E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.447E-06 | 5.791E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.810E-06 | 1.741E-04 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.879E-05 | 5.508E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.824E-04 | 2.159E-03 | FLT3, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.348E-04 | 2.971E-03 | KDR, HIF1A, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.353E-04 | 2.386E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.042E-03 | 7.401E-03 | CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 6.536E-04 | 5.156E-03 | CA2, CA4 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.350E-03 | 8.714E-03 | POLB, APEX1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
